

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Thursday, January 26, 2006

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
		<i>DB=PGPB,USPT,EPAB; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L14	L13 and l1	3
<input type="checkbox"/>	L13	l2 and l9	25
<input type="checkbox"/>	L12	L11 and l2	2
<input type="checkbox"/>	L11	L10 and l9	17
<input type="checkbox"/>	L10	(424/130.1,141.1,155.1,617)![CCLS]	3435
<input type="checkbox"/>	L9	(warrell or grant or brown).in.	42536
<input type="checkbox"/>	L8	(warrell or grant or brwon).in.	8573
<input type="checkbox"/>	L7	20020197256.pn.	1
<input type="checkbox"/>	L6	L5 and L4	4
<input type="checkbox"/>	L5	L1.clm.	129
<input type="checkbox"/>	L4	L2.clm.	74
<input type="checkbox"/>	L3	L2 and L1	134
<input type="checkbox"/>	L2	gallium nitrate	1186
<input type="checkbox"/>	L1	rituximab	1301

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUIDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:05:09 ON 26 JAN 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.89

1.89

FILE 'REGISTRY' ENTERED AT 07:10:35 ON 26 JAN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 JAN 2006 HIGHEST RN 872575-89-8
DICTIONARY FILE UPDATES: 24 JAN 2006 HIGHEST RN 872575-89-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E "GALLIUM NITRATE"/CN 25

E1	1	GALLIUM NIOBIUM ZINC OXIDE/CN
E2	1	GALLIUM NIOBIUM ZIRCONIUM OXIDE (GA4NB4ZRO18)/CN
E3	1 -->	GALLIUM NITRATE/CN
E4	1	GALLIUM NITRATE (GA(NO3))/CN
E5	1	GALLIUM NITRATE (GA(NO3)3)/CN
E6	1	GALLIUM NITRATE NONAHYDRATE/CN
E7	1	GALLIUM NITRATE OXIDE (GA(NO3)O)/CN
E8	1	GALLIUM NITRATE OXIDE (GA(NO3)O), COMPD. WITH NITROGEN OXIDE (N2O5) (2:1)/CN
E9	1	GALLIUM NITRIDE/CN
E10	1	GALLIUM NITRIDE (69GAN2)/CN
E11	1	GALLIUM NITRIDE (71GAN)/CN
E12	1	GALLIUM NITRIDE (71GAN2)/CN
E13	1	GALLIUM NITRIDE (GA0.45N0.55)/CN
E14	1	GALLIUM NITRIDE (GA0.52N0.48)/CN
E15	1	GALLIUM NITRIDE (GA0.61N0.39)/CN
E16	1	GALLIUM NITRIDE (GA0.62N0.38)/CN
E17	1	GALLIUM NITRIDE (GA0.6N0.4)/CN
E18	1	GALLIUM NITRIDE (GA0.7N)/CN
E19	1	GALLIUM NITRIDE (GA0.7N0.3)/CN
E20	1	GALLIUM NITRIDE (GA0.95N)/CN
E21	1	GALLIUM NITRIDE (GA1.04N)/CN
E22	1	GALLIUM NITRIDE (GA15N)/CN
E23	1	GALLIUM NITRIDE (GA2N)/CN
E24	1	GALLIUM NITRIDE (GA2N2)/CN
E25	1	GALLIUM NITRIDE (GA2N2), RADICAL ION(1-)/CN

=> S E3

L1 1 "GALLIUM NITRATE"/CN

=> DIS L1 1 SQIDE

THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 13494-90-1 REGISTRY

CN Nitric acid, gallium salt (8CI, 9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Gallium nitrate (6CI, 7CI)

OTHER NAMES:

CN Gallium nitrate (Ga(NO3)3)

CN Gallium trinitrate

CN Ganite

CN NSC 15200

DR 27425-77-0, 33836-97-4, 39394-16-6

MF Ga . 3 H N O3

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM,
CSNB, DDFU, DIOGENES, DRUGU, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB,
IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS,
NIOSHTIC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER,
USAN, USPAT2, USPATFULL, VTB

(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

DT.CA Caplus document type: Book; Conference; Dissertation; Journal; Patent;
Report


RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties);
RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical
study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP
(Properties); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); CMBI (Combinatorial study); MSC (Miscellaneous); OCCU
(Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
(Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical
study); PREP (Preparation); PRP (Properties); RACT (Reactant or reagent)

CRN (7697-37-2)



● 1/3 Ga

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

718 REFERENCES IN FILE CA (1907 TO DATE)

18 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

722 REFERENCES IN FILE CAPLUS (1907 TO DATE)

8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
7.54	9.43

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 07:11:39 ON 26 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Jan 2006 VOL 144 ISS 5
FILE LAST UPDATED: 25 Jan 2006 (20060125/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l1
L2 723 L1

=> s antibod?
L3 452268 ANTIBOD?

=> s l2 (1) l3
L4 1 L2 (L) L3

=> d ibib 1

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1989:526604 CAPLUS
DOCUMENT NUMBER: 111:126604
TITLE: Combination iron depletion therapy
AUTHOR(S): Taetle, Raymond; Honeysett, J. Michael; Bergeron, Raymond
CORPORATE SOURCE: Cancer Cent., Univ. California, San Diego, CA, USA
SOURCE: Journal of the National Cancer Institute (1989), 81(16), 1229-35
CODEN: JNCIEQ; ISSN: 0027-8874
DOCUMENT TYPE: Journal
LANGUAGE: English

=> d ibib abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1989:526604 CAPLUS
DOCUMENT NUMBER: 111:126604
TITLE: Combination iron depletion therapy
AUTHOR(S): Taetle, Raymond; Honeysett, J. Michael; Bergeron,

Raymond
CORPORATE SOURCE: Cancer Cent., Univ. California, San Diego, CA, USA
SOURCE: Journal of the National Cancer Institute (1989),
81(16), 1229-35
CODEN: JNCIEQ; ISSN: 0027-8874
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Iron (Fe) depletion with anti-transferrin (Tf) receptor monoclonal
antibodies (MAbs), Fe chelators, or gallium (Ga) salts inhibits the growth
of tumor cells. The cytotoxic effects of an IgA anti-human Tf receptor
MAb, 42/6, combined with parabactin, a powerful Fe chelator, or Ga nitrate
were studied in cell cultures. Parabactin inhibited in vitro growth of
human hematopoietic and solid tumor cells, and the rank order of their
sensitivities to the Fe chelator was identical to their relative
sensitivity to MAb 42/6. When the most parabactin and MAb 42/6-sensitive
(HL60 leukemia) and -resistant (KB carcinoma) cells were incubated with
various concns. of parabactin, cell killing was time and dose dependent
over the first 24 h. Little addnl. cytotoxicity occurred when cells were
exposed to parabactin for 48 h. HL60 cells were slightly more sensitive
than KB cells to parabactin cytotoxicity. Addition of anti-Tf receptor MAb
42/6 to parabactin increased cytotoxicity to HL60 cells over a narrow
parabactin dose range but had little effect on cytotoxicity to KB cells.
Cell cycle anal. of cells treated with parabactin for 24 h showed that
doses causing variable cytotoxicity increased the percentage of cells in S
phase, but higher parabactin concns. consistently arrested cells in G1
phase or at the G1/S interface. MAb 42/6 also increased toxicity of
parabactin to granulocyte/macrophage colony-stimulating factors and normal
marrow granulocyte/macrophage progenitors. When HL60 or KB cells were
treated with MAb 42/6 combined with Ga nitrate, MAb 42/6 increased
cytotoxicity of Ga for HL60 cells but had little or no effect on Ga
cytotoxicity to KB cells. MAb 42/6 had minimal effects on cytotoxicity of
the ribonucleotide reductase inhibitor isoquinualdehyde thiosemicarbazone
to either HL60 or KB cells. Both hematopoietic and solid tumors were
killed by Fe depletion, but the hematopoietic cells were more sensitive
than solid tumor cells. Thus, the combined Fe depletion therapy with MAb
42/6 and Fe chelator or Ga salt increased toxicity to MAb 42/6-sensitive
cells, such as HL60, but was not more effective against MAb 42/6-resistant
solid tumor cells. Combination Fe depletion therapy of hematopoietic cell
tumors merits evaluation in in vivo tumor systems.

=> s cancer? or tumor? or neoplas? or lymphom?

281698 CANCER?

415606 TUMOR?

436247 NEOPLAS?

35211 LYMPHOM?

L5 702822 CANCER? OR TUMOR? OR NEOPLAS? OR LYMPHOM?

=> s 15 and 12

L6 113 L5 AND L2

=> s 16 and 13

L7 17 L6 AND L3

=> s 117 not py>2002

L17 NOT FOUND

The L-number entered could not be found. To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s 17 not py>2002

3474993 PY>2002

L8 9 L7 NOT PY>2002

=> s l8 and rituximab
1238 RITUXIMAB
L9 0 L8 AND RITUXIMAB

=> d l8 ibib 1-4

L8 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:475560 CAPLUS
DOCUMENT NUMBER: 133:109949
TITLE: Pharmaceutical compositions for treatment of diseased tissues
INVENTOR(S): Lee, Clarence C.; Lee, Feng-Min
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040269	A2	20000713	WO 2000-US191	20000105
WO 2000040269	A3	20001130		
W: AU, CA, CN, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1999-114906P	P 19990105

L8 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:227537 CAPLUS
DOCUMENT NUMBER: 132:262172
TITLE: Use of neoangiogenesis markers for diagnosis and treatment of **tumors**
INVENTOR(S): Krause, Werner; Muschick, Peter
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000018439	A2	20000406	WO 1999-EP7198	19990929
WO 2000018439	A3	20000914		
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, ES, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19845798		A1	20000413	DE 1998-19845798
PRIORITY APPLN. INFO.:			DE 1998-19845798	A 19980929

L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:736476 CAPLUS
DOCUMENT NUMBER: 131:346535
TITLE: Use of neomycin for treating angiogenesis-related diseases
INVENTOR(S): Hu, Guo-Fu; Vallee, Bert L.

PATENT ASSIGNEE(S): The Endowment for Research In Human Biology, Inc., USA
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958126	A1	19991118	WO 1999-US10269	19990511
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2331620	AA	19991118	CA 1999-2331620	19990511
AU 9939804	A1	19991129	AU 1999-39804	19990511
EP 1083896	A1	20010321	EP 1999-922915	19990511
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6482802	B1	20021119	US 2000-700436	20001109
PRIORITY APPLN. INFO.:			US 1998-84921P	P 19980511
			WO 1999-US10269	W 19990511
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L8 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1998:385263 CAPLUS
 DOCUMENT NUMBER: 129:130935
 TITLE: Transferrin receptor-dependent and -independent iron transport in gallium-resistant human lymphoid leukemic cells
 AUTHOR(S): Chitambar, Christopher R.; Wereley, Janine P.
 CORPORATE SOURCE: Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, 53226, USA
 SOURCE: Blood (1998), 91(12), 4686-4693
 CODEN: BLOOAW; ISSN: 0006-4971
 PUBLISHER: W. B. Saunders Co.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 18 kwic 3

L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 AB . . . is also directed to pharmaceutical compns. comprising: (a) neomycin or an analog and, optionally, (b) another anti-angiogenic agent or an anti-neoplastic agent. The present invention is further directed to a method for screening neomycin analogs having anti-angiogenic activity. A preferred embodiment. . .
 IT Antitumor agents
 (Wilms' tumor; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
 IT Kidney, neoplasm
 (Wilms', inhibitors; neomycin, its analogs and other agents for

treatment of angiogenesis-related diseases)

IT Nerve, **neoplasm**
(acoustic neuroma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Skin, **neoplasm**
(basal cell carcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Lung, **neoplasm**
(carcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Uterus, **neoplasm**
(cervix, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Intestine, **neoplasm**
(colon, carcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Ovary, **neoplasm**
(cystadenocarcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Brain, **neoplasm**
(ependymoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Blood vessel, **neoplasm**
(hemangioma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Blood vessel, **neoplasm**
(hemangiosarcoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Liver, **neoplasm**
(hepatoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Ovary, **neoplasm**

Pancreas, **neoplasm**

Testis, **neoplasm**
(inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Adipose tissue, **neoplasm**
(liposarcoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(**lymphoma**; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Brain, **neoplasm**

Brain, **neoplasm**
(medulloblastoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT **Antibodies**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Angiogenic factors
Hepatocyte growth factor
Interleukin 8
Platelet-derived growth factors
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(neomycin and analogs are inhibitors of nuclear translocation of angiogenic factors for treatment of angiogenesis-related diseases)

IT Notochord
(**neoplasm**, chordoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Mammary gland
Prostate gland
Sweat gland
Sweat gland
(**neoplasm**, inhibitors; neomycin, its analogs and other agents
for treatment of angiogenesis-related diseases)

IT Nerve, **neoplasm**
Nerve, **neoplasm**
(neuroblastoma, inhibitors; neomycin, its analogs and other agents for
treatment of angiogenesis-related diseases)

IT Skin, **neoplasm**
(pseudoxanthoma elasticum; neomycin, its analogs and other agents for
treatment of angiogenesis-related diseases)

IT Kidney, **neoplasm**
(renal cell carcinoma, inhibitors; neomycin, its analogs and other
agents for treatment of angiogenesis-related diseases)

IT Eye, **neoplasm**
(retinoblastoma, inhibitors; neomycin, its analogs and other agents for
treatment of angiogenesis-related diseases)

IT Testis, **neoplasm**
(seminoma, inhibitors; neomycin, its analogs and other agents for
treatment of angiogenesis-related diseases)

IT Lung, **neoplasm**
(small-cell carcinoma, inhibitors; neomycin, its analogs and other
agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(synovial membrane **tumor** inhibitors; neomycin, its analogs
and other agents for treatment of angiogenesis-related diseases)

IT Synovial membrane
(**tumors**, inhibitors; neomycin, its analogs and other agents
for treatment of angiogenesis-related diseases)

IT 50-18-0, Cyclophosphamide 50-35-1, Thalidomide 50-44-2,
6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-18-3,
Triethylenemelamine 51-21-8, Fluorouracil 51-75-2, Mechlorethamine
51-79-6, Urethane 52-24-4, Triethylenethiophosphoramidate 52-67-5,
D-Penicillamine 53-19-0, Mitotane 53-79-2, Puromycin 54-25-1,
6-Azauridine 54-91-1, Pipobroman 55-98-1, Busulfan 57-22-7,
Vincristine 58-05-9, Folinic acid 58-19-5, Dromostanolone 59-05-2,
Methotrexate 66-75-1, Uracil mustard 68-76-8, Triaziquone 69-33-0,
Tubercidin 84-16-2, Hexestrol 89-38-3, Pteropterin 115-02-6,
Azaserine 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea
147-94-4, Cytarabine 148-82-3, Melphalan 151-56-4D, Aziridine,
derivs., biological studies 154-42-7, Thioguanine 154-93-8, Carmustine
157-03-9, 6-Diazo-5-oxo-L-norleucine 302-22-7, Chlormadinone acetate
302-49-8, Uredepa 302-70-5, Mechlorethamine oxide hydrochloride
305-03-3, Chlorambucil 320-67-2, Azacitidine 362-07-2,
2-Methoxyestradiol 459-86-9, Mitoguazone 477-30-5, Demecolcine
488-41-5, Mitobronitol 494-03-1, Chlornaphazine 520-85-4,
Medroxyprogesterone 522-40-7, Fosfestrol 545-55-1,
Triethylenephosphoramidate 555-77-1, 2,2',2''-Trichlorotriethylamine
566-48-3, Formestane 576-68-1, Mannomustine 595-33-5, Megestrol
acetate 642-83-1, Aceglatone 645-05-6, Altretamine 801-52-5,
Porfiromycin 865-21-4, Vinblastine 968-93-4, Testolactone 1402-44-4,
Actinomycin F1 1404-00-8, Mitomycin 1404-15-5, Nogalamycin
1508-45-8, Podophyllinic acid 2-ethyl hydrazide 1661-29-6, Meturedopa
1936-40-9, Novembichin 1954-28-5, Etoglucid 1980-45-6, Benzodepa
2363-58-8, Epitiostanol 2608-24-4, Puposulfan 2998-57-4, Estramustine
3094-09-5, Doxifluridine 3546-10-9, Phenesterine 3733-81-1,
Defosfamide 3778-73-2, Ifosfamide 3819-34-9, Phenamet 3930-19-6,
Streptonigrin 4291-63-8, Cladribine 4342-03-4, Dacarbazine
4533-39-5, Nitracrine 4803-27-4, Anthramycin 5581-52-2, Thiamiprine
5633-18-1, Melengestrol 8052-16-2, Cactinomycin 9014-02-2, Zinostatin
9015-68-3, L-Asparaginase 9042-14-2, Dextran sulfate 10318-26-0,

Mitolactol 10540-29-1, Tamoxifen 11006-70-5, Olivomycin 11056-06-7, Bleomycin 13010-47-4, Lomustine 13311-84-7, Flutamide 13425-98-4, Improsulfan **13494-90-1**, Gallium nitrate 13647-35-3, Trilostane 13665-88-8, Mopidamol 15663-27-1, Cisplatin 17021-26-0, Calusterone 17902-23-7, Tegafur 18378-89-7, Plicamycin 18883-66-4, Streptozocin 20830-81-3, Daunorubicin 21362-69-6, Mepitiostane 21416-67-1, Razoxane 21679-14-1, Fludarabine 22006-84-4, Denopterin 22089-22-1, Trofosfamide 23110-15-8, Fumagillin 23214-92-8, Doxorubicin 24279-91-2, Carboquone 24280-93-1, Mycophenolic acid 28014-46-2, Polyestradiol phosphate 29069-24-7, Prednimustine 29767-20-2, Teniposide 31698-14-3, Ancitabine 33069-62-4, Paclitaxel 33419-42-0, Etoposide 37270-94-3, Platelet factor 4 37339-90-5, Lentinan 41575-94-4, Carboplatin 41992-23-8, Spirogermanium 42471-28-3, Nimustine 50264-69-2, Lonidamine 50935-04-1, Carubicin 51264-14-3, Amsacrine 52128-35-5, Trimetrexate 53123-88-9, Rapamycin 53643-48-4, Vindesine 53714-56-0, Leuprolide 53910-25-1, Pentostatin 54083-22-6, Zorubicin 54749-90-5, Chlorozotocin 55726-47-1, Enocitabine 56420-45-2, Epirubicin 57773-63-4, Triptorelin 57982-77-1, Buserelin 57998-68-2, Diaziquone 58066-85-6, Miltefosine 58337-35-2, Elliptinium acetate 58957-92-9, Idarubicin 58970-76-6, Ubenimex 58994-96-0, Ranimustine 61163-28-8, β -1,3-Glucan sulfate 61422-45-5, Carmofur 61825-94-3, Oxaliplatin 62435-42-1, Perfosfamide 63612-50-0, Nilutamide 64431-69-2, Aclacinomycin S 65271-80-9, Mitoxanthrone 65646-68-6, Fenretinide 65807-02-5, Goserelin 68247-85-8, Peplomycin 70052-12-9, Eflornithine 70563-58-5, Herbimycin A 71628-96-1, Menogaril 72496-41-4, Pirarubicin 72732-56-0, Piritrexim 74913-06-7, Chromomycin 78186-34-2, Bisantrone 80576-83-6, Edatrexate 82413-20-5, Droloxifene 84088-42-6, Roquinimex 85622-93-1, Temozolomide 86090-08-6, Angiostatin 87806-31-3, Porfimer sodium 89149-10-0, 15-Deoxyspergualin 89778-26-7, Toremifene 90357-06-5, Bicalutamide 92118-27-9, Fotemustine 95058-81-4, Gemcitabine 98631-95-9, Sobuzoxane 99519-84-3, CAI 100286-90-6 102676-47-1, Fadrozole 103775-75-3, Miboplatin 106486-76-4, Carzinophilin 110690-43-2, Emitefur 112809-51-5, Letrozole 112887-68-0, Tomudex 114977-28-5, Docetaxel 120511-73-1, Anastrozole 123948-87-8, Topotecan 126509-46-4, Eponemycin 126595-07-1, Propagermanium 129298-91-5, AGM 1470 130370-60-4, Batimastat 142298-75-7, Ribonuclease inhibitor 154039-60-8, Marimastat 187888-07-9, Endostatin 188417-67-6, CM 101 196858-78-3 197850-48-9 197850-49-0 250331-65-8 250593-25-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

=> d 18 abs 3

L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AB The present invention is directed to using neomycin or an analog thereof as a therapeutic agent to treat angiogenesis-related diseases, which are characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells. The present invention is also directed to pharmaceutical compns. comprising: (a) neomycin or an analog and, optionally, (b) another anti-angiogenic agent or an anti-**neoplastic** agent. The present invention is further directed to a method for screening neomycin analogs having anti-angiogenic activity. A preferred embodiment of the invention relates to using neomycin to treat subjects having such diseases. A dose of 20 ng neomycin/embryo or higher completely inhibited angiogenin-induced angiogenesis in the chorioallantoic membrane (CAM) assay. Neomycin inhibits angiogenin-induced angiogenesis mainly through inhibition of nuclear translocation of angiogenin.

=> file pctfull		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	28.84	38.27
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25

FILE 'PCTFULL' ENTERED AT 07:15:47 ON 26 JAN 2006
 COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 3 JAN 2006 <20060103/UP>
 MOST RECENT UPDATE WEEK: 200552 <200552/EW>
 FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> UPDATING DELAYED DUE TO DELIVERY FORMAT CHANGES. <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOT YET AVAILABLE IN THIS FILE.
 USE IPC7 FORMAT FOR SEARCHING THE IPC. WATCH THIS SPACE FOR FURTHER
 DEVELOPMENTS AND SEE OUR NEWS SECTION FOR FURTHER INFORMATION
 ABOUT THE IPC REFORM <<<

=> s gallium nitrate
 12196 GALLIUM
 17 GALLIUMS
 12203 GALLIUM
 (GALLIUM OR GALLIUMS)
 31552 NITRATE
 8697 NITRATES
 36228 NITRATE
 (NITRATE OR NITRATES)
 L10 547 GALLIUM NITRATE
 (GALLIUM(W)NITRATE)

=> s cancer? or tumor? or neoplas? or lymphom?
 74539 CANCER?
 62442 TUMOR?
 21534 NEOPLAS?
 17294 LYMPHOM?
 L11 93747 CANCER? OR TUMOR? OR NEOPLAS? OR LYMPHOM?

=> s 110/clm
 3101 GALLIUM/CLM
 5022 NITRATE/CLM
 L12 52 (GALLIUM NITRATE/CLM)
 ((GALLIUM(W)NITRATE)/CLM)

=> s antibod?
 L13 84196 ANTIBOD?

=> s 112 and 113
 L14 28 L12 AND L13

=> s 114 and 111
 L15 27 L14 AND L11

=> s rituximab
 1144 RITUXIMAB

5 RITUXIMABS
L16 1144 RITUXIMAB
(RITUXIMAB OR RITUXIMABS)

=> s 116 and 115
L17 6 L16 AND L15

=> s 113/clm
L18 32952 (ANTIBOD?/CLM)

=> s 118 and 112
L19 18 L18 AND L12

=> s 119 and 116
L20 3 L19 AND L16

=> d ibib 1-3

L20 ANSWER 1 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2005112973 PCTFULL ED 20051206 EW 200548
TITLE (ENGLISH): SENSITIZATION TO ANOTHER ANTICANCER THERAPY AND/OR
AMELIORATION OF A SIDE EFFECT OF ANOTHER ANTICANCER
THERAPY BY TREATMENT WITH A GST-ACTIVATED ANTICANCER
COMPOUND
TITLE (FRENCH): SENSIBILISATION A UNE AUTRE THERAPIE ANTICANCEREUSE
ET/OU AMELIORATION D’UN EFFET SECONDAIRE
D’UNE AUTRE THERAPIE ANTICANCEREUSE A
L’AIDE D’UN TRAITEMENT IMPLIQUANT UN
COMPOSE ANTICANCEREUX ACTIVE PAR GST
INVENTOR(S): BROWN, Gail, L., 2995 Woodside Road #400, Woodside,
California 94062, US [US, US];
KECK, James, G., 617 Harbor Colony Court, Redwood City,
California 94062, US [US, US];
WICK, Michael, M., 2995 Woodside Road #400, Woodside,
California 94062, US [US, US]
PATENT ASSIGNEE(S): TELIK INC., 3165 Porter Drive, Palo Alto, California
94304, US [US, US], for all designates States except
US;
BROWN, Gail, L., 2995 Woodside Road #400, Woodside,
California 94062, US [US, US], for US only;
KECK, James, G., 617 Harbor Colony Court, Redwood City,
California 94062, US [US, US], for US only;
WICK, Michael, M., 2995 Woodside Road #400, Woodside,
California 94062, US [US, US], for US only
AGENT: ENG, Hugo M.\$, Foley & Lardner LLP, 1530 Page Mill
Road, Palo Alto, California 94304\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 2005112973	A1	20051201

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO
CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR
HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU
LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL
PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA
UG US UZ VC VN YU ZA ZM ZW

RW (ARIPO): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT

	LT LU MC NL PL PT RO SE SI SK TR
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.:	WO 2005-US17960 A 20050519
PRIORITY INFO.:	US 2004-60/572,790 20040520

L20 ANSWER 2 OF 3	PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:	2004060317 PCTFULL ED 20040726 EW 200430
TITLE (ENGLISH):	COMBINATION OF GALLIUM COMPOUNDS WITH NONCHEMOTHERAPEUTIC ANTICANCER AGENTS IN THE TREATMENT OF NEOPLASIA
TITLE (FRENCH):	COMBINAISON DE COMPOSES A BASE DE GALLIUM ET D'AGENTS ANTICANCEREUX NON CHIMIOOTHERAPEUTIQUES DESTINEE AU TRAITEMENT DE LA NEOPLASIE
INVENTOR(S):	WARRELL, Raymond, P., Jr., 6 Kimball Circle, Westfield, NJ 07090, US [US, US]; GRANT, Stefan, C., 200 West 90th Street, Apartment 24-H, New York, NY 10128, US [US, US]; BROWN, Bob, D., 54 Leprechaun Drive, Long Hill Township, NJ 07946, US [US, US]
PATENT ASSIGNEE(S):	GENTA INCORPORATED, Two Connell Drive, Berkeley Heights, NJ 07922, US [US, US], for all designates States except US; WARRELL, Raymond, P., Jr., 6 Kimball Circle, Westfield, NJ 07090, US [US, US], for US only; GRANT, Stefan, C., 200 West 90th Street, Apartment 24-H, New York, NY 10128, US [US, US], for US only; BROWN, Bob, D., 54 Leprechaun Drive, Long Hill Township, NJ 07946, US [US, US], for US only
AGENT:	BIRDE, Patrick, J.\$, Kenyon and Kenyon, One Broadway, New York, NY 10004\$, US
LANGUAGE OF FILING:	English
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

	NUMBER	KIND	DATE
	-----	-----	-----
	WO 2004060317	A2	20040722

DESIGNATED STATES	
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO):	BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM
RW (EPO):	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.:	WO 2003-US41746 A 20031231
PRIORITY INFO.:	US 2002-60/437,275 20021231

L20 ANSWER 3 OF 3	PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:	2004045593 PCTFULL ED 20040608 EW 200423
TITLE (ENGLISH):	COMBINATION CANCER THERAPY WITH A GST-ACTIVATED ANTICANCER COMPOUND AND ANOTHER ANTICANCER THERAPY
TITLE (FRENCH):	POLYTHERAPIE ANTICANCEREUSE AU MOYEN D'UN COMPOSE ANTICANCEREUX ACTIVE PAR GST ET D'UN AUTRE TRAITEMENT ANTICANCEREUX
INVENTOR(S):	XU, Hua, 1567 Samedra Street, Sunnyvale, CA 94087, US; BROWN, Gail, L., 2995 Woodside Road, #401, Woodside, CA 94062, US; SCHOW, Steven, R., 204 Mendocino Way, Redwood City, CA 94065, US;

KECK, James, G., 617 Harbor Colony Court, Redwood City,
 CA 94065, US
 PATENT ASSIGNEE(S): TELIK, INC., 3165 Porter Drive, Palo Alto, CA 94304, US
 [US, US]
 AGENT: NGUYEN, Sam, L.\$, Heller, Ehrman White & McAuliffe LLP,
 275 Middlefield Road, Menlo Park, CA 94025-3506\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2004045593	A2	20040603

DESIGNATED STATES
 W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO
 CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR
 HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV
 MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU
 SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN
 YU ZA ZM ZW
 RW (ARIPO): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU
 MC NL PT RO SE SI SK TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 APPLICATION INFO.: WO 2003-US36209 A 20031114
 PRIORITY INFO.: US 2002-60/426,983 20021115

=> d his

(FILE 'HOME' ENTERED AT 07:05:09 ON 26 JAN 2006)

FILE 'REGISTRY' ENTERED AT 07:10:35 ON 26 JAN 2006
 E "GALLIUM NITRATE"/CN 25

L1 1 S E3

FILE 'CAPLUS' ENTERED AT 07:11:39 ON 26 JAN 2006

L2 723 S L1
 L3 452268 S ANTIBOD?
 L4 1 S L2 (L) L3
 L5 702822 S CANCER? OR TUMOR? OR NEOPLAS? OR LYMPHOM?
 L6 113 S L5 AND L2
 L7 17 S L6 AND L3
 L8 9 S L7 NOT PY>2002
 L9 0 S L8 AND RITUXIMAB

FILE 'PCTFULL' ENTERED AT 07:15:47 ON 26 JAN 2006

L10 547 S GALLIUM NITRATE
 L11 93747 S CANCER? OR TUMOR? OR NEOPLAS? OR LYMPHOM?
 L12 52 S L10/CLM
 L13 84196 S ANTIBOD?
 L14 28 S L12 AND L13
 L15 27 S L14 AND L11
 L16 1144 S RITUXIMAB
 L17 6 S L16 AND L15
 L18 32952 S L13/CLM
 L19 18 S L18 AND L12
 L20 3 S L19 AND L16